Merck & Co. Stock

$80.30

0.34% yesterday

NYSE, Aug 12, 10:12 pm CET

ISIN

US58933Y1055

Symbol

MRK

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Merck & Co. Stock price

$80.30

+1.46 1.86% 5Y

NYSE, Closing price Tue, Aug 12 2025

+0.27 0.34%

ISIN

US58933Y1055

Symbol

MRK

Reports

Quarter | Annual

Index

Dow Jones, NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$199.9b

Enterprise Value

$226.7b

Net debt

$26.8b

Cash

$8.6b

Shares outstanding

2.5b

Valuation (TTM | estimate)

P/E

12.3 | 8.9

P/S

3.1 | 3.0

EV/Sales

3.6 | 3.5

EV/FCF

15.4

P/B

4.1

Dividends

DPS

$3.12

Yield 1Y | 5Y

3.9% | 3.0%

Growth 1Y | 5Y

5.4% | 7.7%

Payout 1Y | 3Y

46.3% | 70.5%

Increased

14 Years

Financials (TTM | estimate)

Revenue

$63.6b | $65.6b

EBITDA

$28.5b | $30.3b

EBIT

$23.9b | $27.2b

Net Income

$16.4b | $22.4b

Free Cash Flow

$14.7b

Growth (TTM | estimate)

Revenue

1.8% | 2.3%

EBITDA

3.4% | 5.4%

EBIT

1.9% | 12.2%

Net Income

19.4% | 31.1%

Free Cash Flow

12.0%

Financial Health

Equity Ratio

39.6%

Return on Equity

37.0%

ROCE

26.1%

ROIC

20.7%

Debt/Equity

0.7

EPS

$6.5

FCF per Share

$5.9

Short interest

1.3%

Employees

74k

Rev per Employee

$870.0k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Merck & Co. Stock Analysis

Unlock Scores for Free

32 Analysts have issued a Merck & Co. forecast:

19x Buy

59%

13x Hold

41%

More details on Analyst Estimates Including Price Targets

32 Analysts have issued a Merck & Co. forecast:

Buy

59%

Hold

41%

Analyst Estimates with Stock Price Targets

Financial data from Merck & Co.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	63,616 63,616	2% 2% 100%
- Direct Costs	13,794 13,794	9% 9% 22%
Gross Profit	49,822 49,822	5% 5% 78%
- Selling and Administrative Expenses	10,733 10,733	3% 3% 17%
- Research and Development Expense	15,221 15,221	13% 13% 24%
EBITDA	28,469 28,469	3% 3% 45%
- Depreciation and Amortization	4,601 4,601	12% 12% 7%
EBIT (Operating Income) EBIT	23,868 23,868	2% 2% 38%
Net Profit	16,406 16,406	19% 19% 26%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Merck & Co. Stock News

Neutral

Seeking Alpha

●

about 10 hours ago

10 Undervalued Dividend Growth Stocks: August 2025

I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the top ten stocks for consideration. I use two valuation screens, one based on my fair value estimate, and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with addition...

Neutral

Business Wire

●

about 15 hours ago

KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. In this study, KEYTRUDA® (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv), given bef...

Positive

The Motley Fool

●

3 days ago

2 Magnificent Stocks to Buy That Are Near 52-Week Lows

The S&P 500 has a miserly yield of 1.2%. The average healthcare stock's yield is about 1.8%.

More Merck & Co. News

Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Head office	United States
CEO	Robert Davis
Employees	74,000
Founded	1891
Website	www.merck.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now